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Summary
 
Inducible gene expression is primarily regulated at the level of transcription. Additional steps of
“processing” pre-mRNA, involved in the regulation of induced gene expression, have not
been previously reported. Here we report a novel mechanism of “activation-induced splicing”
of preexisting tumor necrosis factor (TNF) message (pre-mRNA) in naive T lymphocytes after
engagement of the T cell receptor (TCR), which still occurs after inhibition of transcription.
Expression of TNF has been previously demonstrated to be regulated at both the transcrip-
tional and translational levels. However, neither the large pool of TNF mRNA observed in ac-
tivated T cells nor TNF protein production, which peaks very shortly after activation, can be
solely attributed to increased transcription. Evidence is presented that activation-induced splic-
ing of TNF pre-mRNA plays a significant role in the rapid production of TNF seen in acti-
vated T cells. Activation triggers processing of TNF pre-mRNA that has accumulated in naive
T cells (before activation-induced transcription), and the mature TNF mRNA is translocated
to the cytoplasm for rapid translation and protein production. This novel form of activation-induced
splicing of TNF may allow T cells to mount an immediate response to activation stimuli under
physiological conditions.
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T
 
NF is one of the most potent cytokines and plays a
critical role in host defense, immune regulation, and
inflammatory responses. For more than two decades, ex-
tensive studies have revealed an intriguing regulatory
mechanism for TNF expression. Like many other cyto-
kines, TNF production can be detected after activation of
various cell types (including macrophages and T and B
lymphocytes) by mitogens such as LPS or PMA/ionomycin
(1–3). However, a striking feature that distinguishes TNF
from other cytokines is that TNF production can very rap-
idly reach a high level in the bloodstream in response to ac-
tivation stimuli. Endotoxins such as LPS induce a massive
production of TNF by macrophages in a very short time
which may lead to lethal shock. Anti-CD3 antibody ad-
ministration causes severe clinical symptoms in both hu-
mans and animals due to the rapid and massive release of
TNF by activated T lymphocytes (4–6). However, the
mechanism(s) that allows this rapid, massive production of
TNF is not fully understood.
The expression of TNF is regulated at multiple levels.
Activation increases transcription of the TNF gene. Activa-
tion also triggers posttranscriptional regulatory mechanisms.
T cell TNF mRNA is stabilized by “costimulatory” signal-
ing through CD28 molecules during T cell activation (7).
The translation of TNF mRNA in macrophages is con-
trolled by an endotoxin-responsive element (8). However,
the three- to fivefold peak increase in transcription of the
TNF gene detected in both activated macrophages and T
cells, in addition to mRNA stabilization detected in T cells,
cannot explain the 100-fold increase in TNF mRNA or
the massive protein production seen in these activated cells
(9, 10). Another previous observation was that resting T
lymphocytes express TNF mRNA at low levels (11, 12),
although TNF protein is not detectably produced (13, 14).
These studies suggested the possibility of a posttranscrip-
tional regulatory mechanism distinct from mRNA stability.
Splicing of pre-mRNA has been described as a potential
regulatory mechanism for the expression of IL-1
 
b
 
 and IL-2
(15, 16). Both IL-1
 
b
 
 and IL-2 mRNA can be super-
induced by cycloheximide, a protein synthesis inhibitor
that facilitates the processing of pre-mRNA to mature
spliced mRNA. Cycloheximide similarly superinduces
TNF mRNA (17). Since the TNF gene consists of three
introns and four exons (18), the transcript must be pro-
cessed for protein production (see Fig. 1 
 
A
 
). In studies re-
ported below, we describe a novel form of posttranscrip-
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tional regulation involved in the rapid TNF protein
production seen after activation of T cells.
 
Materials and Methods
 
CD4
 
1
 
 T Cell Purification, Activation, and Fractionation.
 
CD4
 
1
 
T cells were purified from spleens and lymph nodes of 12-wk-old
female BALB/cJ mice using MiniMacs magnetic separation
(Miltenyi Biotec Inc., Sunnyvale, CA). CD4
 
1
 
 T cells were cul-
tured at 3
 
 3 
 
10
 
6
 
 cells/ml for the indicated times with or without
antibodies as indicated. For activation, the T cells were first incu-
bated with purified anti-CD3 antibody (145.2C11) and anti-
CD28 antibody (whenever indicated; PharMingen, San Diego,
CA) for 30 min on ice. The cells were then washed, incubated
with anti–hamster IgG antibody (PharMingen) for 30 min on ice,
and activated at 37
 
8
 
C for the times indicated. Antibodies were
used at a concentration of 10 mg/ml. PMA (10 ng/ml) and iono-
mycin (1 mM) were added at the time of activation.
For the experiments of [
 
3
 
H]uridine incorporation, CD4
 
1
 
 T
cells were incubated with 2 mCi [
 
3
 
H]uridine (Du Pont-NEN,
Boston, MA) in triplicate wells in a 96-well plate. In the indicated
wells, actinomycin D (Act.D;
 
1
 
 Sigma Chemical Co.), 2 mg/ml,
and/or PMA/ionomycin were added. For transcription inhibi-
tion, the T cells were first incubated with 10 mg/ml Act.D for 1 h
in a 37
 
8
 
C incubator. After cooling down on ice, the cells were
incubated with anti-CD3 antibody followed by anti–hamster IgG
antibody cross-linking at 4
 
8
 
C. Activation time began when the
cells were incubated at 37
 
8
 
C after cooling.
For fractionation of nuclei and cytoplasm, T cells were sus-
pended in a solution containing 50 mM KCl, 80 mM NaCl, 2 mM
MgCl
 
2
 
, 4% glycerol, and 10 mM Hepes, pH 7.4. 0.05% NP-40
was added on ice for 3 min. Nuclei were spun down gently and
nuclear RNA was prepared using the RNeasy kit (QIAGEN,
Inc., Chatsworth, CA). The supernatant was cleared by full-speed
centrifugation on a microfuge and mixed with an equal volume
of 7 M urea, 10 mM EDTA, 0.35 M NaCl, and 20 mM Tris-
HCl, pH 8.0. The cytoplasmic RNA was prepared by phenol ex-
traction from the mix.
 
Reverse Transcription–PCR and Northern Blot Analysis.
 
Equal num-
bers of CD4
 
1
 
 T cells were harvested and total RNA was prepared
using the RNeasy kit (QIAGEN, Inc.). The RNA concentration
was determined for each sample and 2.5 mg total RNA was used
in the reverse transcription (RT) reactions. Equal amounts of
cDNA were then used in PCR reactions. PCR primers used for
TNF mRNA detection were (
 
a
 
) 5
 
9
 
 end: ATGAGCACA-
GAAAGCATGATCCGCGAC; and (
 
b
 
) 3
 
9
 
 end: TCACAGAG-
CAATGACTCCAAAGTAGACCTG. The PCR reactions were
performed under the following conditions: 94
 
8
 
C, 1.5 min; 62
 
8
 
C,
2 min; 72
 
8
 
C, 2 min for 32 cycles and PCR products were ana-
lyzed on a 2% agarose gel. To further confirm the specificity of
the PCR products, the bands on the gels were transferred to ny-
lon membranes and hybridized with a 
 
32
 
P-labeled probe, GT-
GCTCCTCACCCACACCGTC. RT-PCR for expression of
the 
 
HPRT
 
 gene (hypoxanthine phosphoribosyltransferase) was
performed to demonstrate the relative quantity of mRNA in each
sample. PCR primers for
 
 HPRT
 
 mRNA were (
 
a
 
) 5
 
9
 
 end:
GTAATGATCAGTCAACGG; (
 
b
 
) 3
 
9
 
 end: CCAGCAAGC-
TTGCAACC. The sequence for the 
 
HPRT
 
 hybridization probe
was CAAGCTTGCAACCTTAAC. PCR primers for
 
 bcl-
 
2 gene
were (5
 
9
 
 primer) TTGAAGTGCCATTGGTAC and (3
 
9
 
 primer)
GCTGGGGCATATAGTTCCACA-AAGGCATC. For North-
ern blot analysis, 20 mg of total RNA for each sample was used.
A PCR fragment containing a 252-bp exon 4 sequence of the
TNF gene was purified, nick translated, and used as the probe.
 
Results
 
TCR Engagement Induced Both Transcription and Splicing of
TNF Pre-mRNA.
 
To determine pre- and mature TNF
mRNA in naive and activated T cells, RT-PCR analysis
was used with primers designed in the first and the fourth
exons (from the ATG translation initiation codon at the 5
 
9
 
end and the TGA stop codon at the 3
 
9
 
 end of the TNF
gene; see Fig. 1 
 
A
 
). The expected PCR products include
both unprocessed transcripts and spliced mRNA. CD4
 
1
 
 T
cells were isolated from BALB/cJ mice and activated
 
 
 
by
cross-linking with anti-CD3 and anti-CD28. RT-PCR
was then performed with cDNA prepared from both naive
and activated CD4
 
1
 
 T cells. Two major TNF PCR prod-
ucts were detected. In the absence of TCR engagement,
the dominant PCR product was a 1.7-kb cDNA fragment.
Within 15 min after activation, high-level expression of a
0.7-kb fragment, representing mature TNF mRNA, was
detected (Fig. 1 
 
B
 
). Expression of the 0.7-kb fragment
peaked 3 h after activation and decreased gradually thereaf-
ter. Interestingly, the 1.7-kb fragment was detected with
decreased intensity immediately after activation; however,
the intensity of the 1.7-kb fragment was slightly increased
24 h after TCR engagement (the intensity of the 0.7-kb
fragment had greatly diminished by 24 h). In contrast,
PCR assays demonstrated a consistent expression of HPRT
mRNA during the 24 h after T cell activation. Since the
PCR protocol allowed a proportional amplification of both
the 1.7- and 0.7-kb fragments (Fig. 1 
 
C
 
), the reciprocal
changes of intensity between these two bands reflected
changes in the two RNA transcripts after activation.
Both the 1.7- and 0.7-kb cDNA fragments were cloned
and sequenced, and the data obtained demonstrated that
the 1.7-kb fragment contained all four exons and three in-
trons of the TNF gene (pre-mRNA, 1688 bp; reference
18), whereas the 0.7-kb fragment contained only the exon
sequences of the TNF gene (708 bp). The 1.7-kb fragment
was not detected by PCR when RNA of naive T cells was
processed in the absence of reverse transcriptase; thus, the
1.7-kb fragment represented TNF pre-mRNA accumu-
lated in naive T cells. The decrease in the 1.7-kb fragment
and the marked increase in the 0.7-kb fragment after TCR
engagement indicated that there was a preexisting accumu-
lation of TNF pre-mRNA in naive CD4
 
1
 
 T cells, and that
activation of the T cells induced splicing of this TNF pre-
mRNA, in addition to transcription of the TNF gene. This
activation-induced splicing of TNF pre-mRNA disap-
peared within 24 h of activation.
Since anti-CD28 treatment has been shown to stabilize
mature TNF mRNA (7), the increased level of mature
TNF mRNA in activated T cells may be partially due to
the accumulation of “stabilized” mRNA. To determine
 
1
 
Abbreviations used in this paper:
 
 Act.D, actinomycin D; HPRT, hypoxan-
thine phosphoribosyltransferase; RT, reverse transcription. 
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the role of the activation signal in posttranscriptional pro-
cessing in the absence of mRNA stabilization, CD4
 
1
 
 T
cells were activated by cross-linking with anti-CD3 anti-
body alone. Mature spliced TNF mRNA was markedly in-
creased within 15 min after anti-CD3 cross-linking (Fig. 1
 
B
 
). Within 6 h, the amount of mature TNF mRNA had
increased 10 times (Fig. 1 
 
D
 
). In contrast, total TNF
mRNA (mature 
 
1
 
 pre-mRNA) increased only threefold.
The change in total mRNA reflected the transcriptional
activity and a threefold increase is consistent with the re-
sults of nuclear run-on studies (9). The ratio of mature to
pre-mRNA changed from 
 
.
 
0.4 to 
 
z
 
3 (Fig. 1 
 
D
 
). Thus,
the increased amount of mature TNF mRNA was not due
solely to stabilization and accumulation, but also to efficient
processing (in addition to increased transcription) after acti-
vation.
Northern blot analyses were performed to further con-
firm the accumulation of TNF pre-mRNA in naive CD4
 
1
 
T cells and the splicing of TNF pre-mRNA induced by ac-
tivation. The probe used in the Northern analyses con-
tained the exon 4 sequence which allowed detection of
both TNF pre-mRNA and mature mRNA. Consistent
with the PCR analysis, Northern analysis detected two dis-
tinct TNF bands from the total RNA of CD4
 
1
 
 T cells (Fig.
1 
 
E
 
). In naive T cells, the major band detected by North-
ern blot analysis was of TNF pre-mRNA, which migrated
slightly slower than 28S rRNA. A small amount of mature
TNF mRNA, which ran slightly faster than 18S rRNA,
was also detected. However, 4 h after TCR engagement a
dramatic increase in mature TNF mRNA was seen; how-
ever, TNF pre-mRNA was barely detected. Once again,
the increase of mature TNF mRNA after activation was
concomitant with the decrease of TNF pre-mRNA, indi-
cating that the increase of mature TNF mRNA was the re-
sult of the combination of increased transcription and splic-
ing of TNF pre-mRNA.
 
An Activation Signal Generated by TCR Engagement Is Re-
quired for Efficient Splicing of TNF Pre-mRNA.
 
Various an-
tibodies and mitogens were tested for induction of splicing
of TNF pre-mRNA in CD4
 
1
 
 T cells. Among the antibod-
ies tested, only treatment with anti-CD3 induced splicing
of TNF mRNA, whereas anti-CD28 antibody (as well as
anti-CD4 or anti–H-2K
 
d
 
) treatment alone was unable to
induce splicing of TNF pre-mRNA above the basal level
Figure 1. (A) Schematic rep-
resentation of the structure of
TNF pre-mRNA which in-
cludes four exons (thick lines:
exon 1, 186 bp; exon 2, 55 bp;
exon 3, 48 bp; exon 4, 419 bp;
total 708 bp of coding region)
and  three introns (thin lines: intron
1, 509 bp; intron 2, 177 bp; in-
tron 3, 294 bp; total 980 bp). (B)
Detection of TNF mRNA by
RT-PCR in CD41 T cells acti-
vated by anti-CD3/anti-CD28
or by anti-CD3 alone. In naive
T cells, a significant amount of
TNF pre-mRNA was detected
with a trace amount of mature
mRNA. Anti-CD3 antibody
cross-linking induced a marked
increase in mature mRNA and
decreased pre-mRNA. (C)
Twofold serial dilutions of RNA
were used in the PCR reactions
and resulted in a proportional
decrease of PCR product of
both pre- and mature TNF
mRNA, thus the density of
PCR products reflected the
amount of pre- or mature TNF
mRNA without preferential am-
plification in each reaction. (D)
Densitometry analysis showed
that mature mRNA increased
z10-fold after anti-CD3 activa-
tion whereas the total amount of
TNF mRNA increased only 3.5-
fold. The numbers on the top of
the columns are the ratio of mature/pre-mRNA. (E) Northern blot analysis of total RNA of purified CD41 T cells incubated for 4 h with medium alone
or anti-CD3 and anti-CD28 antibodies. Without antibody cross-linking, a strong band of TNF pre-mRNA and a weak band of mature TNF mRNA
were detected. The antibody cross-linking led to a large amount of mature TNF mRNA. It was not possible to detect decreased TNF pre-mRNA by
Northern blot analysis after activation. 
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(Fig. 2 
 
A
 
). Anti-CD3 activation of T cells is known to trig-
ger calcium influx and induce a cascade of protein phos-
phorylation events (19). It has been demonstrated that cal-
cium influx affects alternative splicing of ATPase mRNA
(20). However, incubation of T cells with ionomycin
alone, which triggers a strong calcium influx, was unable to
induce splicing of TNF pre-mRNA. In contrast, mature
TNF mRNA was increased when T cells were incubated
with PMA. The combination of PMA and ionomycin
greatly increased both transcription and splicing of TNF
pre-mRNA; the intensity of both the TNF pre- and ma-
ture mRNA signals more than tripled (Fig. 2 
 
A
 
).
When RNA was prepared separately from nuclear and
cytoplasmic fractions of resting CD4
 
1
 
 T cells, unspliced
TNF mRNA (pre-mRNA) was the predominant form
seen in the nuclear fraction. No TNF mRNA of either
form was seen in the cytoplasmic fraction of resting CD4
 
1
 
T cells (Fig. 2 
 
B
 
) and no TNF protein production was de-
tected in the culture medium (Fig. 2 
 
C
 
). Activation of rest-
ing CD4
 
1
 
 T cells by PMA/ionomycin strongly induced
splicing of TNF pre-mRNA (Fig. 2 
 
A
 
). After PMA/iono-
mycin activation, mature TNF mRNA was detected in
both the nuclear and cytoplasmic fractions. The mature
TNF mRNA in the cytoplasmic fraction increased with
time after activation, mirrored by a concomitant decrease
in the TNF pre-mRNA in the nuclear fraction (Fig. 2 
 
B
 
).
A marked increase in TNF protein production was also de-
tected after activation (Fig. 2 
 
C
 
). 24 h after activation, cy-
toplasmic TNF mRNA was no longer detected, although
TNF pre-mRNA was again seen in the nuclear fraction
(Fig. 2 
 
B
 
). The concentration of TNF protein in the cul-
ture medium had greatly decreased by 24 h after activation
(Fig 2 
 
C
 
). These results demonstrated that there was nu-
clear accumulation of TNF pre-mRNA but that splicing of
nuclear TNF pre-mRNA in resting CD4
 
1
 
 T lymphocytes
was a slow and inefficient process. The “basal” level of
splicing of TNF pre-mRNA in naive (nonactivated) T cells
did not generate sufficient mature TNF mRNA for protein
production. However, the processing of TNF pre-mRNA
was profoundly (but transiently) upregulated after TCR
engagement. The rapid, efficient processing of nuclear
TNF pre-mRNA induced by T cell activation was accom-
panied by translocation of mature TNF mRNA to the cy-
toplasm and protein production.
To ask whether TCR engagement and resultant T cell
activation may simply reflect heightened efficiency of pre-
mRNA splicing machinery in general, expression of the
 
bcl-
 
2 gene was examined in resting and activated T cells.
The 
 
bcl
 
-2 gene contains a single intron (917 bp) and encodes
two proteins, Bcl-2a and Bcl-2b. Production of Bcl
 
-
 
2a re-
quires splicing, whereas Bcl-2b is derived from unspliced
mRNA (21). RT-PCR was performed to examine both
spliced and unspliced Bcl-2a mRNA from nuclear and cy-
toplasmic fractions of activated and resting CD4
 
1
 
 T cells.
The expected PCR fragment for the unspliced mRNA was
1552 bp and for the spliced mRNA was 635 bp. As shown
in Fig. 2 
 
D
 
, the spliced Bcl-2 mRNA, Bcl-2a, maintained
similar levels in the T cells before and after activation. A
Figure 2. (A) CD41 T cells
were incubated with medium or
various antibodies and reagents
(anti-CD3 [145. 2C11, 10 mg/
ml], anti-CD28 [37.51, 10 mg/
ml; PharMingen], anti-CD4
[GK1.5, 5 mg/ml], anti–H-2Kd
[SF1-1.1, 10 mg/ml; PharMin-
gen], ionomycin [1 mM], and
PMA [10 ng/ml]) for 4 h and
harvested for detection of TNF
expression by RT-PCR. Anti-
CD3 and PMA treatment induced
splicing of TNF pre-mRNA.
Anti-CD28 or ionomycin was
unable to induce efficient splic-
ing of TNF pre-mRNA al-
though a weak band of mature
mRNA indicated a basal level of
processing during the incuba-
tion. (B and C) Expression of
TNF in CD41 T cells activated
by PMA/ionomycin was deter-
mined at the RNA and protein
levels. The purified CD41 T
cells were incubated with PMA
(10 ng/ml)/ionomycin (0.5 mM)
for the times indicated. Total
RNA was separately prepared from nuclear and cytoplasmic fractions for RT-PCR analysis. TNF protein in the culture medium was determined with
the TNF-sensitive cell line L929. TNF protein production coincided with the expression of mature TNF mRNA. (D) Expression of the a forms of Bcl-2
mRNA in the CD41 T cells (nuclear and cytoplasmic fractions) activated by PMA/ionomycin for the times indicated. The same RNA samples were
used as in B. A large amount of mature Bcl-2 mRNA was consistently detected with or without activation of the cells. Only small amounts of pre-
mRNA were detected in the nuclear fractions (upper bands), indicating a constant and efficient splicing of Bcl-2 pre-mRNA in CD41 T cells. 
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weak but consistent band representing the unspliced Bcl-2
mRNA (containing a 917-bp intron) was also detected in
the nuclear fraction. Thus, the splicing machinery was
functioning at a similar efficiency for Bcl-2 pre-mRNA
in CD4
 
1
 
 T cells with or without activation; activation-
induced splicing was specific to the TNF pre-mRNA.
 
Activation-induced Splicing of TNF Pre-mRNA Can Be Dis-
sociated from Transcription. Activation-induced splicing of
pre-mRNA is accompanied by activation-induced tran-
scription; however, as demonstrated above, TNF pre-
mRNA accumulated in the nuclei of naive CD41 T cells
without being spliced until TCR engagement. This obser-
vation suggested that transcription could be dissociated
from activation-induced splicing, and it was possible that
activation-induced splicing was independent of transcrip-
tion. It was also possible that a threshold of TNF pre-
mRNA had to be reached for initiation of efficient splic-
ing. In that case, the splicing event should occur only after
activation-induced transcription. To distinguish between
these two potential mechanisms, we asked whether activa-
tion-induced transcription and splicing of TNF pre-
mRNA in CD41 T cells could be dissociated. Act.D had
been demonstrated to inhibit TNF gene transcription even
in cells that had been activated (8, 9, 14). This was con-
firmed in our studies when we demonstrated that a 1-h in-
cubation of CD41 T lymphocytes with a low dose (2 mg/ml)
of Act.D completely abolished [3H]uridine incorporation
even in the presence of the powerful mitogens PMA and
ionomycin (Fig. 3 A). To ask whether Act.D could block
activation-induced TNF pre-mRNA splicing, CD41 T
cells were incubated with a higher dose of Act.D (10 mg/ml)
for 1 h and then activated by anti-CD3 cross-linking.
Within 5 min, mature TNF mRNA was readily detected
in the Act.D–treated cells and had slightly increased by 15
min after activation (Fig. 3 B). These data demonstrate that
Act.D inhibited activation-induced transcription, but not
activation-induced splicing. However, in the presence of
transcription inhibition, mature TNF mRNA diminished
within 30 min. In contrast, without Act.D, mature TNF
mRNA increased steadily after activation (Fig. 3 C). Inter-
estingly, with or without the transcription inhibitor, no
noticeable increase in the total amount of TNF mRNA,
including pre- and mature mRNA, was detected within
the first 15 min after TCR-mediated activation, though in
both cases, mature TNF mRNA was detected within 5
min of activation (Fig. 3, B and C). The results of nuclear
run-on studies also demonstrated that activation-induced
transcription of the TNF gene was detected 20 min after
cellular activation (17). Thus, splicing of accumulated TNF
pre-mRNA in activated T cells occurs before the initiation
of transcription. A similar result was obtained by incubating
T cells with a high dose (10 mg/ml) of the RNA poly-
merase II inhibitor a-amanitin before TCR cross-linking
(data not shown). Taken together, these results demon-
strate that TCR engagement triggers splicing of TNF pre-
mRNA without requiring transcription. However, spliced
TNF mRNA was unstable with the anti-CD3 signal alone
and degraded rapidly in the presence of the transcription
inhibitor, Act.D (Fig. 3 B). To determine whether spliced
TNF mRNA can be translated in the absence of transcrip-
tion, T cells were activated by PMA/ionomycin in the
presence of Act.D (Fig. 3 D). A significant amount of ma-
ture TNF mRNA was detected 3 h after activation. Thus,
it appears that PMA/ionomycin treatment may not only
induce splicing, but may also stabilize TNF mRNA. In ad-
dition, the cells activated by PMA/ionomycin in the pres-
ence of Act.D produced a substantial amount of TNF pro-
tein (Fig. 3 E). Splicing of TNF pre-mRNA can be
triggered independently of transcription and, when pre-
mRNA is processed, protein is produced; thus, activation-
induced splicing is physiologically relevant.
Discussion
Splicing serves as a mechanism to regulate gene expres-
sion in development and differentiation, and “regulators”
have been identified for tissue-specific splicing (22, 23). Al-
though little is known about the role of splicing in regula-
tion of gene expression in acute response to stimuli, it is
clear that splicing is involved in gene regulation during
cellular activation. For example, alternative splicing of
mRNA of certain proteins occurs in response to activation
signals (20, 24). This study presents the first clear evidence
of a critical role of activation-induced splicing in gene ex-
pression after T cell activation. In naive T cells, splicing of
TNF pre-mRNA is an inefficient process that results in the
accumulation of TNF pre-mRNA in the nucleus. The
splicing of all introns of TNF pre-mRNA is triggered rap-
idly by TCR engagement, and this activation-induced
splicing is followed by TNF protein production. Thus,
splicing of nuclear pre-mRNA can be a regulating factor in
induced gene expression. In addition, activation-induced
splicing only occurred for a short time after TCR engage-
ment (possibly as little as 12 h), and activation-induced
splicing was apparently reversible. The reversible process
and different signal requirements distinguish activation-
induced splicing of TNF pre-mRNA from alternative
splicing. The mechanism(s) of activation-induced splicing
remains unclear. However, in human T cells, splicing of
TNF pre-mRNA, but not other cytokine mRNAs, can be
specifically inhibited by 2-aminopurine (25), suggesting an
mRNA-specific splicing regulator. In naive T cells, this
regulator may block the nuclear processing of TNF pre-
mRNA. When T cells are activated, the regulator may be
released from TNF pre-mRNA allowing the pre-mRNA
to be quickly processed. In the later stages of activation, the
regulator molecules may again accumulate, bind to TNF
pre-mRNA, and stop the splicing of TNF pre-mRNA.
Whether such an mRNA-specific splicing regulator can be
identified remains an interesting question. It will also be in-
teresting to study whether activation-induced splicing is in-
volved in the regulation of expression of other cytokines,
presumably using different regulator(s).252 Activation-induced Splicing
Transcription and splicing are highly coordinated for the
expression of many genes. However, transcriptional activ-
ity without splicing of pre-mRNA has been observed in
the expression of both IL-1 and IL-2 genes (15, 16). Here
we provide evidence that splicing of TNF pre-mRNA in
naive CD41 T cells occurs after an activation signal(s) in
the absence of transcription. The coordination and dissoci-
ation of transcription and splicing may be controlled by dif-
ferent mechanisms to allow genes to be constitutively ac-
tive or for genes for which function is transiently required.
The mature mRNA of cytokines degrades rapidly due to a
conserved AU sequence in the 39 untranslated region (26,
27). The dissociation of transcription and splicing may re-
sult in nuclear accumulation of the cytokine pre-mRNA
that is relatively stable and can be released as functionally
mature mRNA after appropriate activation stimuli. The
mechanism of activation-induced splicing may thus facili-
tate an immediate response to activation stimuli.
TNF is a cytokine with powerful inflammatory effects
involving many autoimmune diseases in animal models
(28–30), thus expression of TNF has to be tightly con-
trolled. However, TNF is one of the major players in hy-
peracute responses (31), mounts the first line of host de-
fense, and triggers a cascade of immune response (32, 33).
Particularly in T cells, TNF is the first cytokine produced
after activation, followed by many others (34). Thus,
whereas TCR-mediated activation-induced splicing of
TNF pre-mRNA allows and may enhance the immediate
alarm signal after T cell receptor engagement and multiple
layers of regulation, including transcription, splicing, RNA
stability, translation, and posttranslational events, ensure the
accurate regulation of TNF expression.
Figure 3. (A) Effects of low dose Act.D (2 mg/ml) on RNA synthesis. CD41 T cells (2 3 106/
ml) were cultured in a 96-well plate and pulsed with 2 mCi [3H]uridine at the times indicated. T
cells were cultured with: M, medium alone; P, PMA/ionomycin; and D, Act.D and PMA/iono-
mycin. Lack of incorporation of [3H]uridine indicated the complete inhibition of RNA synthesis
by Act.D even in the presence of PMA/ionomycin. (B) Effect of high dose Act.D (10 mg/ml)
preincubation on the processing of TNF mRNA. T cells were incubated with Act.D (10 mg/ml)
for 1 h at 378C, the cells were then cross-linked with anti-CD3 on ice for 20 min. They were in-
cubated at 378C to allow activation and collected at the time points indicated. Mature TNF
mRNA was detected at 5 and 15 min but diminished thereafter. The amount of TNF pre-mRNA
was also reduced due to splicing in the absence of transcription. (C) Mature TNF mRNA in-
creased steadily after anti-CD3 activation in the absence of Act.D. However, similar to the data
presented in B, mature TNF mRNA was detected within 5 min of activation. However, the in-
crease of TNF mRNA, including pre- and mature mRNA, was not seen until 15 min after activa-
tion, indicating that the time required for transcription initiation lagged behind that for activation-
induced splicing. (D) T cells were also incubated with medium alone (M); medium and Act.D
(M1D); PMA/ionomycin (P1I); and PMA/ionomycin and Act.D, (P1I1D). T cells were incu-
bated with Act.D for 1 h before the addition of PMA/ionomycin. The spliced TNF mRNA was
still detected 3 h after activation in the presence of Act.D. (E) TNF protein production in the
presence of transcription inhibitors added as in D.253 Yang et al.
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